Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2022)
14 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 20, 2022
Slide 1: Proxy Season Update April 2022
Proxy Season Update April 2022
Slide 2: Our mission
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases 2 Our mission
Slide 3: 2021 A Year of Strong Performance
2021 A Year of Strong Performance Continued to strengthen our diversified portfolio with leading positions in Oncology, Hematology, Cardiovascular and Immunology A 9% increase in total revenues* Significant pipeline progress with several key regulatory milestones: received eight approvals in the U.S
Slide 4: Company Response to COVID-19
Company Response to COVID-19 4 Expanded patient support programs to help eligible unemployed patients in the U.S. Expanded access to free BMS medicines, including some of our most widely prescribed products & those prescribed via telehealth services. Ensured no interruption in supplying medicines to
Slide 5: Our Commitment to Sustainability
Our Commitment to Sustainability 5 Embracing environmental stewardship Environment 2024 Science-based emissions reduction targets established 2030 100% renewable electricity 2040 Net neutral GHG 100% EV fleet 100% equitable water use Zero waste to landfill Promoting product quality & safety Cultivat
Slide 6: Our Commitment to Diversity and Inclusion
Our Commitment to Diversity and Inclusion 6 Supplier Diversity Employee Giving Workforce Representation Clinical Trial Diversity Reach underserved communities in urban and rural U.S. geographies; train and develop 250 new investigators Identify and activate under-utilized sites in the most racially
Slide 7: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance 7 Board Accountability and Shareholder Rights Regular shareholder engagement Annual election of Directors Majority voting standard for election of Directors Robust Lead Independent Director role Limit on public company board memberships for BMS Directors (4) L
Slide 8: Board Well Equipped to Support Company Strategies
Board Well Equipped to Support Company Strategies 8 KEY SKILLS & EXPERIENCE Healthcare ü ü ü ü ü ü ü ü ü Science/Technology/Innovation ü ü ü ü ü ü ü Financial ü ü ü ü ü ü ü ü Risk Management ü ü ü ü ü ü ü ü Sales & Marketing ü ü ü ü ü International ü ü ü ü ü ü ü ü Public Company CEO/CFO ü ü ü ü ü Ac
Slide 9: Executive Compensation Supporting our Strategy
Executive Compensation Supporting our Strategy Continued Commitment to our Compensation Philosophy and Structure Sound Compensation Governance Practices 100% performance-based annual and long-term incentives Caps on payouts under annual and long-term incentive award programs Robust share ownership a
Slide 10: 2021 Compensation Plan: Supports Successful Completion of Celgene Integration
2021 Compensation Plan: Supports Successful Completion of Celgene Integration & Execution of Core Strategy 10 Base Salary Annual Incentive (Paid in cash) Allows us to attract and retain talent in a highly competitive labor market Based on specialized qualifications, experience and role impact, and p
Slide 11: 2022 Compensation Plan: Supports Revenue Renewal & Execution of Core Strategy
2022 Compensation Plan: Supports Revenue Renewal & Execution of Core Strategy 11 Base Salary Annual Incentive (Paid in cash) Allows us to attract and retain talent in a highly competitive labor market Based on specialized qualifications, experience and role impact, and pay levels of comparable posit
Slide 12: We Value Your Support at Our 2022 Annual Meeting
We Value Your Support at Our 2022 Annual Meeting 12 FOR Election of Directors FOR Advisory Vote to Approve the Compensation of our Named Executive Officers FOR Approval of the Appointment of an Independent Registered Public Accounting Firm AGAINST Lowering the Ownership Threshold for Special Shareho
Slide 13: We Value Your Support at Our 2022 Annual Meeting (continued)
We Value Your Support at Our 2022 Annual Meeting (continued) 13 Shareholder Proposal on the Adoption of a Board policy that the Chairperson of the Board be an Independent Director After careful consideration, the Board did not feel that this proposal deserved its support. The Board believes differen
Slide 14: Forward-Looking Information and Non-GAAP Financial Information
Forward-Looking Information and Non-GAAP Financial Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual
Bristol Myers Squibb — Shareholder Meeting (April 2022) on 6ix